Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

ImmunityBio, Inc. (IBRX) had Revenue of $14.74M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$14.74M
Net Income	$-413.56M
Cost of Goods Sold	--
Gross Profit	$14.74M
Operating Expenses	$358.93M
Operating Income	$-344.18M
Non-Operating Income/Expense	$-69.46M
Pre-Tax Income	$-413.64M
Normalized Pre-Tax Income	$-413.64M
Income after Taxes	$-413.64M
Income from Continuous Operations	$-413.64M
Consolidated Net Income/Loss	$-413.64M
Normalized Income after Taxes	$-413.64M
EBIT	$-344.18M
EBITDA	$-305.53M
Weighted-Average Shares Outstanding (Basic)	697.31M
Weighted-Average Shares Outstanding (Diluted)	700.44M
Earnings per Share (EPS) (Basic)	$-0.59
Earnings per Share (EPS) (Diluted)	$-0.62
Balance Sheet Financials
Current Assets	$184.59M
Property, Plant, and Equipment	$137.09M
Long-Term Assets	$198.35M
Total Assets	$382.93M
Current Liabilities	$54.94M
Long-Term Debt	$461.88M
Long-Term Liabilities	$816.12M
Total Liabilities	$871.06M
Common Equity	$-488.13M
Tangible Shareholders Equity	$-504.06M
Shareholders Equity	$-488.13M
Common Shares Outstanding	852.90M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-391.24M
Cash Flow from Investing Activities	$-12.25M
Cash Flow from Financial Activities	$281.63M
Beginning Cash	$265.79M
End Cash	$143.91M
Increase/Decrease in Cash	$-121.88M
Stock-Based Compensation	$34.43M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.36
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-17.59
Debt to Equity Ratio	-0.95
Gross Margin	100.00%
Operating Margin	-2334.23%
EBIT Margin	-2334.23%
EBITDA Margin	-2072.09%
Pre-Tax Profit Margin	-2805.32%
Profit Margin	-2804.77%
Free Cash Flow	$-398.12M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.04
Inventory Turnover	--
Receiveable Turnover	6.25
Days Sales in Receivables	58.42
Return on Equity	84.74%
Return on Tangible Equity	82.06%
Return on Assets	-108.02%
Return on Investments	1575.67%
Book Value Per Share	$-0.57
Free Cash Flow per Share	$-0.57
Operating Cash Flow per Share	$-0.56

Data from Zacks Investment Research, Inc.